Modify and re-phrase this: However, increased toxicity was observed with bevacizumab in…
- User
Modify and re-phrase this: However, increased toxicity was observed with bevacizumab in this study, with a higher incidence of grade 3 or greater thromboembolism and gastrointestinal and genitourinary fistua. The experience with bevacizumab demonstrates the utility of adding a non-chemotherapeutic agent to the treatment armamentarium for advanced cervical cancer, but highlights the ongoing need for novel therapies that improve clinical outcomes and are well tolerated. In recent years, immune-checkpoint inhibitors have shown antitumor activity in multiple tumor types. Programmed death 1 (PD-1) is a T-cell coinhibitory receptor that functions in an immunoregulatory capacity under normal conditions. PD-1 plays a significant role in cancer by contributing to the ability of a tumor to evade immunosurveillance. Given the presence of a virus leading to antigen production in the oncogenesis of cervical cancer, evaluating immune checkpoint inhibition as a treatment strategy in this setting is of great interest. Notably, PD-L1 expression has been identified in virus-induced cancers, and an upregulation of PD-1 and PD-L1 has been reported in high-risk HPV-associated cervical intraepithelial neoplasia. Pembrolizumab is a highly selective, fully humanized monoclonal antibody that prevents the interaction between PD-1 and its ligands, programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). In the multicohort phase 1b KEYNOTE-028 study, pembrolizumab monotherapy showed promising antitumor activity and manageable safety in patients with previously treated, PD-L1–positive advanced cervical cancer.
- Assistant
However, this study observed an increase in toxicity when using bevacizumab, including a higher occurrence of grade 3 or worse thromboembolism and gastrointestinal and genitourinary fistulas. While the use of bevacizumab in treating advanced cervical cancer demonstrates the benefits of adding a non-chemotherapeutic agent to the treatment approach, it also emphasizes the ongoing requirement for new therapies that improve clinical outcomes and are well tolerated.
Recently, immune-checkpoint inhibitors have displayed antitumor activity in various tumor types. Programmed death 1 (PD-1) is a T-cell receptor that normally functions in immunoregulation. However, in cancer, PD-1 contributes to a tumor's ability to evade the immune system. Considering the presence of a virus that leads to antigen production in cervical cancer, evaluating immune checkpoint inhibition as a treatment strategy is of great interest.
It is worth noting that virus-induced cancers, like cervical intraepithelial neoplasia associated with high-risk HPV, have shown an upregulation of PD-1 and PD-L1. Pembrolizumab, a fully humanized monoclonal antibody, selectively prevents the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
In a multicohort phase 1b study called KEYNOTE-028, pembrolizumab as a monotherapy demonstrated promising antitumor activity and manageable safety in patients with previously treated, PD-L1-positive advanced cervical cancer.